%0 Journal Article
%T P-glycoprotein inhibitors as an adjunct therapy for TB.
%A Parida KK
%A Lahiri M
%A Ghosh M
%A Dalal A
%A Kalia NP
%J Drug Discov Today
%V 29
%N 9
%D 2024 Sep 19
%M 39032811
%F 8.369
%R 10.1016/j.drudis.2024.104108
%X The primary challenge in TB treatment is the emergence of multidrug-resistant TB (MDR-TB). One of the major factors responsible for MDR is the upregulation of efflux pumps. Permeation-glycoprotein (P-gp), an efflux pump, hinders the bioavailability of the administered drugs inside the infected cells. Simultaneously, angiogenesis, the formation of new blood vessels, contributes to drug delivery complexities. TB infection triggers a cascade of events that upregulates the expression of angiogenic factors and P-gp. The combined action of P-gp and angiogenesis foster the emergence of MDR-TB. Understanding these mechanisms is pivotal for developing targeted interventions to overcome MDR in TB. P-gp inhibitors, such as verapamil, and anti-angiogenic drugs, including bevacizumab, have shown improvement in TB drug delivery to granuloma. In this review, we discuss the potential of P-gp inhibitors as an adjunct therapy to shorten TB treatment.